Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Merck
Cantor Fitzgerald
Medtronic
Chubb
Fuji
Julphar

Generated: March 20, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for Vedolizumab

« Back to Dashboard

US Patents for Vedolizumab

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Vedolizumab ➤ Try a Free Trial Methods of treating ulcerative colitis MILLENNIUM PHARMACEUTICALS, INC. (Cambridge, MA) ➤ Try a Free Trial
Vedolizumab ➤ Try a Free Trial Formulation for anti-.alpha.4.beta.7 antibody Millennium Pharmaceuticals, Inc. (Cambridge, MA) ➤ Try a Free Trial
Vedolizumab ➤ Try a Free Trial Nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein CureVac AG (Tubingen, DE) ➤ Try a Free Trial
Vedolizumab ➤ Try a Free Trial Methods of treating ulcerative colitis Millennium Pharmaceuticals, Inc. (Cambridge, MA) ➤ Try a Free Trial
Vedolizumab ➤ Try a Free Trial Method of treating an inflammatory bowel disease comprising agonists of orexin-1 receptor INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (Paris, FR) UNIVERSITE PARIS DIDEROT--PARIS 7 (Paris, FR) ASSISTANCE PUBLIQUE--HOPITAUX DE PARIS (Paris, FR) ➤ Try a Free Trial
Vedolizumab ➤ Try a Free Trial Anti-human OX40L antibodies and methods of treating graft versus host disease with the same Kymab Limited (Cambridge, GB) ➤ Try a Free Trial
Vedolizumab ➤ Try a Free Trial Nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein CureVac AG (Tubingen, DE) ➤ Try a Free Trial
Drugname Patent Number Patent Title Patent Assignee Estimated Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

International Patents for Vedolizumab

Drugname Country Document Number Estimated Expiration Related US Patent
Vedolizumab Argentina 086237 2031-05-02 ➤ Try a Free Trial
Vedolizumab Australia 2012250873 2031-05-02 ➤ Try a Free Trial
Vedolizumab Australia 2016231469 2031-05-02 ➤ Try a Free Trial
Vedolizumab Australia 2018278866 2031-05-02 ➤ Try a Free Trial
Vedolizumab Canada 2834867 2031-05-02 ➤ Try a Free Trial
Vedolizumab Canada 3028209 2031-05-02 ➤ Try a Free Trial
Vedolizumab Chile 2017000830 2031-05-02 ➤ Try a Free Trial
Drugname Country Document Number Estimated Expiration Related US Patent

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Harvard Business School
US Army
Chubb
Argus Health
UBS
Julphar

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.